Prozac-makers promise disclosure

Eli Lilly, which developed the Prozac anti-depressant, said it is to disclose more data on past and present clinical trials, to counter criticism that drug-makers hush up negative findings, the Wall Street Journal reported.

The company will issue data from early to late-stage trials once a drug is being sold, including results that were contrary to the expected outcome.

The new policy poses a risk to Lilly because plaintiffs’ lawyers could use early test results in product liability lawsuits.